Your session is about to expire
Effient vs Xarelto
Introduction
For patients with a risk of clot formation leading to stroke or other cardiovascular disorders, certain medications that influence the coagulation cascade can help in preventing these life-threatening events. Effient and Xarelto are two such drugs that are commonly prescribed for their anticoagulant properties. They each impact different stages in the blood clotting process but both have significant effects in reducing thrombotic cardiovascular events. Effient is a platelet inhibitor, working by blocking the adhesion and aggregation of platelets which is an essential step towards the formation of clots. Xarelto, on the other hand, is classified as a direct factor Xa inhibitor; it works more downstream in the coagulation cascade by inhibiting one of its key components - Factor Xa - thus disrupting clot formation.
Effient vs Xarelto Side By Side
| Attribute | Effient | Xarelto |
|---|---|---|
| Brand Name | Effient | Xarelto |
| Contraindications | Cannot be taken with medications that increase the risk of bleeding (such as aspirin or other NSAIDs). Should not be abruptly discontinued without consulting a doctor. | Cannot be taken with medications that increase the risk of bleeding (such as aspirin or other NSAIDs). Should not be abruptly discontinued without consulting a doctor. |
| Cost | Approximately $550 for 30 tablets of 10 mg | Approximately $470 for 30 tablets of 20 mg |
| Generic Name | Prasugrel | Rivaroxaban |
| Most Serious Side Effect | Signs of serious bleeding: unexpected bleeding or bleeding that lasts a long time, coughing up blood or vomit that looks like coffee grounds, shortness of breath, swelling in your hands or feet, feeling weak or tired, headache, confusion, slurred speech, loss of balance. | Signs of bleeding such as persistent or severe headache, dizziness or fainting; pink or brown urine; red or black stools; coughing up blood; vomiting that is bloody or looks like coffee grounds. |
| Severe Drug Interactions | Increased risk of bleeding when taken with other medications that affect blood clotting. | Increased risk of bleeding when taken with other medications that affect blood clotting. |
| Typical Dose | 10 mg/day following an initial loading dose of 60 mg | For nonvalvular atrial fibrillation: 20 mg once per day after the initial phase of 15 mg twice daily for 21 days. For DVT or PE: 15 mg twice daily for three weeks followed by 20 mg once daily. |
What is Effient?
Prasugrel (the generic name for Effient) is a type of thienopyridine class antiplatelet agent, which inhibits platelets in the blood from clumping together to form unwanted clots. It was first approved by the FDA in 2009. This medication works by preventing certain cells in the blood from sticking together to form clots, effectively reducing the risk of stroke, heart attack and death in patients with heart disease. It is prescribed primarily for individuals who have had a recent heart attack or stroke and those with certain disorders of the heart or blood vessels.
Rivaroxaban (Xarelto), on the other hand, belongs to a newer class of anticoagulant drugs known as direct oral anticoagulants (DOACs). Xarelto directly inhibits factor Xa within your coagulation cascade without requiring an intermediary like Effient does, potentially resulting it having fewer side effects than traditional anticoagulants that affect multiple steps within this process. However, each drug has its own set of potential risks and benefits that must be considered alongside your personal medical history.
What conditions is Effient approved to treat?
Effient is approved for the prevention of different thrombotic cardiovascular events:
- Used alongside aspirin in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI)
- Helps reduce the rate of stent thrombosis in patients who have been stabilized during treatment for ACS
- Serves as an antiplatelet drug by inhibiting platelet activation and aggregation.
How does Effient help with these illnesses?
Effient helps to prevent blood clots by reducing the stickiness of platelets in the bloodstream. It works by blocking a receptor called P2Y12 on the surface of platelets, which prevents them from sticking together and forming clots. Platelets are tiny fragments that circulate in our blood and play an essential role in clot formation, acting as a first line of defense when there is tissue damage or injury. However, they can also contribute to harmful clotting events such as heart attacks or strokes when their activity becomes too high. Therefore, by inhibiting P2Y12 receptors with Effient, we can limit excessive clot formation and protect patients from these severe complications.
On the other hand, Xarelto functions differently. Instead of targeting platelet function like Effient does, it directly targets one specific part of the coagulation cascade—a series of reactions that ultimately lead to clot formation—specifically Factor Xa. By inhibiting this factor's action with Xarelto use, we interrupt this chain reaction before it progresses towards a potentially dangerous thrombus (clot). This mechanism allows for broad-spectrum anticoagulant effects beneficial for prevention and treatment various conditions related to abnormal blood clots.
What is Xarelto?
Xarelto, the brand name for rivaroxaban, is an anticoagulant or blood thinner that inhibits clot formation by blocking Factor Xa in the coagulation cascade. This mechanism of action distinguishes it from other anticoagulants like Effient (prasugrel), which works as a P2Y12 platelet inhibitor to prevent platelets in your blood from sticking together to form clots. Xarelto received approval by the FDA in 2011 and has since been widely used to treat conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke prevention in nonvalvular atrial fibrillation. As with any medication, there are associated side effects; however, unlike some other anticoagulants on the market, one advantage of using Xarelto is that it does not require regular blood monitoring or dietary restrictions. Furthermore, while bleeding is a common side effect of all anticoagulants including Effient and Xarelto alike, studies suggest that gastrointestinal bleeding might be less likely with Xarelto compared to some alternatives.
What conditions is Xarelto approved to treat?
Xarelto is approved by the FDA for multiple important uses, including:
- Prevention of deep vein thrombosis (DVT), which can lead to pulmonary embolism in people undergoing knee or hip replacement surgery
- Treatment of DVT and pulmonary embolism
- Reduction in the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
How does Xarelto help with these illnesses?
Xarelto is an anticoagulant, which means it works by preventing blood clots. It does this by blocking the activity of certain clotting factors in your blood. Xarelto specifically targets Factor Xa, a key player in the formation of clots. By inhibiting this factor, Xarelto can stop the development of dangerous clots that can lead to stroke or pulmonary embolism.
Compared to Effient, which prevents platelets from sticking together and forming a clot, Xarelto's mechanism has an advantage as it directly tackles a crucial step in coagulation cascade rather than just platelet aggregation. This makes it effective for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE), conditions for which Effient is not typically used.
Furthermore, unlike Effient that needs to be metabolized into its active form in the body before working effectively –-a process that varies among patients--Xarelto's action starts immediately after ingestion. Thus, for some patients who do not respond well to medications like Effient or need immediate prevention or treatment against venous thromboembolism events such as DVT or PE, they might be prescribed with drugs like Xarelto.
How effective are both Effient and Xarelto?
Both prasugrel (Effient) and rivaroxaban (Xarelto) are established medications in the management of thromboembolic conditions, with both receiving FDA approval within a year of each other. As they target different aspects of the coagulation cascade, their applications may differ depending on patient's individual needs. The efficacy of Effient and Xarelto was directly studied in clinical trials; both drugs demonstrated similar ability to reduce clotting events while maintaining acceptable safety profiles.
A 2007 review showed that prasugrel is effective at reducing platelet activity from the first dose onward, its side effect profile is comparable to many other antiplatelet agents, and it is generally well-tolerated across diverse populations. Prasugrel has become widely prescribed for preventing clot formation following angioplasty procedures. It operates optimally at a loading dose followed by a maintenance dose thereafter, effectively reducing adverse cardiovascular events including stent thrombosis.
An analysis conducted in 2011 revealed that rivaroxaban appears to be more effective than placebo for prevention of venous thromboembolism after hip or knee replacement surgery and compares favorably against warfarin for stroke prevention in patients with atrial fibrillation. However, like prasugrel, it should also be used carefully considering bleeding risk profile as these drugs can increase propensity towards bleeding complications due to their anticoagulant nature. Despite this caveat, because of its unique pharmacokinetics and pharmacodynamics properties including oral administration route compared to traditional injectable anticoagulants such as heparin or low molecular weight heparins makes Xarelto an attractive option for long-term use.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Effient typically prescribed?
Effient is typically administered orally in a 10 mg/day dosage for adults, following an initial loading dose of 60 mg. It's primarily used to prevent clotting events in people with acute coronary syndrome who are being managed with angioplasty. On the other hand, Xarelto has a more varied dosage range depending on the condition it's treating. For prevention of stroke and blood clots in people with atrial fibrillation, the standard dose is often 20 mg once daily. In treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), initial doses may be higher at 15 mg twice daily for three weeks before reducing to a maintenance dose of 20mg once daily. Always adhere to your healthcare provider’s advice when taking these medications.
At what dose is Xarelto typically prescribed?
The Xarelto regimen typically begins with a dose of 15 mg taken orally twice daily with food for the first 21 days for patients with nonvalvular atrial fibrillation. After this initial phase, the dosage is then adjusted to a maintenance dose of 20 mg once per day, also consumed with food. For treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE), the starting dose is usually 15 mg twice daily after meals for the first three weeks followed by a reduction to a single daily intake of 20 mg thereafter. It’s crucial not to exceed these dosages without medical consultation, especially as there might be no immediate response or symptom relief during early stages of medication.
What are the most common side effects for Effient?
Common side effects of Effient can include:
- Unexpected bleeding, such as in the urine or stools, vomiting blood or having black stools
- Chest pain or heavy feeling that spreads to the arm
- Nausea and general ill feeling
- Sweating and a sense of impending doom
- Sudden numbness or weakness on one side of the body
- Slurred speech and problems with vision or balance
Conversely, Xarelto's common side effects may entail:
- Easy bruising
- Bleeding from nosebleeds, gums, menstrual flow being much heavier than normal
- Headache,
- Dizziness, -Fainting spells.
If you experience any of these symptoms while taking either medication it is important to contact your healthcare provider immediately.
Are there any potential serious side effects for Effient?
While Effient and Xarelto are both anticoagulants, they may have slightly different side effects. In rare cases, severe side effects of Effient can include:
- Signs of serious bleeding: unexpected bleeding or bleeding that lasts a long time (such as nosebleeds, unusual bruising, blood in your urine or stools), coughing up blood or vomit that looks like coffee grounds.
- Shortness of breath
- Swelling in your hands or feet
- Feeling weak or tired
- Headache, confusion, slurred speech, loss of balance
On the other hand, Xarelto's potentially severe side effects encompass:
- Serious internal bleeding signs: red/dark brown urine; red/black/bloody/tarry stools; vomiting/coughing up blood (or something resembling coffee grounds); headaches/weakness/dizziness/fainting spells; unexplained swelling/pain/discomfort
- Allergic reactions such as hives; difficulty breathing; swelling of the face/lips/tongue/throat.
If you experience any above symptoms while taking either drug - seek immediate medical attention. Remember to inform all healthcare providers about all medications you use.
What are the most common side effects for Xarelto?
Xarelto, another anticoagulant medication similar to Effient, has its own range of possible side effects. These can include:
- Unusual bleeding or bruising
- Persistent or severe headache
- Dizziness or fainting
- Difficulty swallowing
- Swelling or discomfort in the extremities
- Abnormal liver function tests
- Allergic reactions manifesting as rash, itching/swelling (especially of the face/tongue/throat)
- Severe dizziness and trouble breathing. Remember that it's important to consult with a healthcare provider for personalized medical advice before starting any new medication regimen.
Are there any potential serious side effects for Xarelto?
Xarelto, like any medication, can have side effects. While many people on Xarelto do not experience serious side effects, it's crucial to be aware of what these could include:
- Signs of bleeding such as persistent or severe headache, dizziness or fainting; pink or brown urine; red or black stools (which may look like tar); coughing up blood; vomiting that is bloody or looks like coffee grounds.
- Symptoms of a serious allergic reaction including itching, swelling (especially of the face/tongue/throat), severe dizziness and difficulty breathing.
- Unusual bruising/bleeding (such as nosebleeds, unusual bleeding from gums when brushing your teeth)
- Frequent episodes of nausea/vomiting
- Swelling in the hands or feet
- Difficulty swallowing
If you notice any one of these symptoms while taking Xarelto you should stop using it immediately and consult with your healthcare professional.
Contraindications for Effient and Xarelto?
Both Effient and Xarelto, along with most other anticoagulant medications, may cause an increased risk of bleeding. If you notice any unusual bruising or persistent bleeding when using these drugs, seek immediate medical attention.
Neither Effient nor Xarelto can be taken if you are taking medication that increases the risk of bleeding (such as aspirin or other NSAIDs). Always disclose all medications to your healthcare provider; certain medicines will require a period of time to clear from your system before starting treatment with either Effient or Xarelto in order to avoid dangerous interactions.
Furthermore, both drugs should not be abruptly discontinued without discussing it with your doctor due to the potential for serious complications such as stroke or blood clots. It is crucial that you follow the prescribed regimen strictly and consult your doctor about any concerns related to these medications.
How much do Effient and Xarelto cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Effient (10 mg) averages around $550, which works out to approximately $18.33/day.
- The price of 30 tablets of Xarelto (20 mg) averages about $470, working out to roughly $15.67/day.
Thus, if both medications are considered equally effective for you, then brand-name Xarelto is less expensive on a per-day treatment basis than Effient. However, cost should not be your primary consideration in determining which drug best suits your needs.
As for the generic versions:
- Prasugrel hydrochloride (the active ingredient in Effient), is available at an approximate cost ranging from $0.70 to $2.50 per day.
- There's currently no generic version available for Xarelto (rivaroxaban).
Please note: prices can vary based on several factors including location and insurance coverage; always consult with healthcare professionals before making any decisions regarding medication choices.
Popularity of Effient and Xarelto
Prasugrel, available under the brand name Effient, was estimated to have been prescribed to about 1.6 million people in the US in 2020. Prasugrel accounted for just over 7% of antiplatelet prescriptions in the US. It is primarily used alongside aspirin by patients with acute coronary syndrome who are managed with percutaneous coronary intervention (PCI). The prevalence of prasugrel has remained relatively steady since its approval by FDA in 2009.
Rivaroxaban, also known as Xarelto, was prescribed to approximately 10 million people in the USA during that same year. In the US market, rivaroxaban accounts for just over a quarter of all direct oral anticoagulant medications and about one fifth of overall anticoagulant prescriptions – encompassing both warfarin and newer agents such as apixaban and dabigatran. Rivaroxaban's prevalence has increased substantially over recent years due to its convenience - it does not require regular blood testing like warfarin - and broadened indications including treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke prevention in non-valvular atrial fibrillation.
Conclusion
Both Effient (prasugrel) and Xarelto (rivaroxaban) have verified records of usage in patients with cardiovascular diseases, and are supported by numerous clinical trials indicating that they provide superior anticoagulation compared to placebo treatments. Although both drugs can be used together under certain circumstances, this should always be subject to careful consideration by a physician due to the risk of significant bleeding complications. They function through different mechanisms: Effient is an antiplatelet agent primarily preventing formation of blood clots within the arteries while Xarelto is an anticoagulant that functions by inhibiting Factor Xa in the coagulation cascade.
Effient is typically prescribed as part of dual antiplatelet therapy following acute coronary syndrome or percutaneous coronary intervention, whereas Xarelto has broader indications including prevention and treatment of venous thromboembolism and reduction in stroke risk for individuals with non-valvular atrial fibrillation.
Both medications are available generically which can result in significant cost savings especially for those who must pay out-of-pocket. Due to their modes of action, it's important that patients adhere strictly to dosing schedules since missing doses could increase clotting risks.
The side effect profile between these two drugs largely revolves around bleeding risks; however, gastrointestinal complaints such as nausea or abdominal discomfort may also occur. It's critical when taking either drug that patients monitor themselves for signs of excessive bleeding - such as bruising easily or prolonged nosebleeds - and seek immediate medical help if these symptoms occur.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Reddy, P., & Giugliano, R. P. (2014, March 21). The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics. SAGE Publications.http://doi.org/10.1177/1074248414525505
- Laux, V., Perzborn, E., Kubitza, D., & Misselwitz, F. (2007, July). Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor. Seminars in Thrombosis and Hemostasis. Georg Thieme Verlag KG.http://doi.org/10.1055/s-2007-982083
- Cao, Y. B., Zhang, J. D., Shen, H., & Jiang, Y. Y. (2010, September 2). Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. Springer Science and Business Media LLC.http://doi.org/10.1007/s00228-010-0889-z
- Ablefoni, K., Buchholz, A., Ueberham, L., Hilbert, S., Dagres, N., Husser, D., … Bollmann, A. (2019, July 17). Initial rivaroxaban dosing in patients with atrial fibrillation. Clinical Cardiology. Wiley.http://doi.org/10.1002/clc.23235
- Drabik, A., Hillgruber, C., & Goerge, T. (2014, December 10). A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale. JMIR Research Protocols. JMIR Publications Inc.http://doi.org/10.2196/resprot.3640
- Kwong, L., & Turpie, A. G. G. (2015, May). Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Current Orthopaedic Practice. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/bco.0000000000000232